Ketamine is legal nationwide and FDA-approved as esketamine; psilocybin has strong trial data but legal access only in Oregon and Colorado.
Choosing between ketamine vs psilocybin comes down to a few practical questions: what is legal where you live, what your budget allows, and what the evidence supports for your condition. Both are studied for depression, anxiety, and other hard-to-treat conditions. But they are very different drugs with very different access rules. This guide compares them side by side so you can see which fits your situation today.
Ketamine is the option you can actually get right now. It is legal in all 50 states, has FDA approval in its esketamine form, and works within hours. Psilocybin shows very promising trial results and may feel more "complete" in a single experience. But you cannot get it by prescription, and legal access exists only in Oregon and Colorado. For most people today, the choice is shaped by access first and preference second.
| Factor | Ketamine | Psilocybin |
|---|---|---|
| Legal status (US) | Schedule III. Legal nationwide via clinics and telehealth. | Schedule I federally. Regulated access only in Oregon and Colorado. |
| FDA status | Esketamine (Spravato) FDA-approved; off-label ketamine also used. | Not FDA-approved. Holds Breakthrough Therapy designation. |
| How it works | NMDA glutamate receptor antagonist (a dissociative). | 5-HT2A serotonin receptor agonist (a classic psychedelic). |
| Evidence strength | Strong short-term antidepressant data; durability needs repeat dosing. | Two positive Phase 3 trials in 2025; long-term real-world data still limited. |
| Session experience | 40–60 min of dissociation; full series often 6+ sessions. | One 6–8 hour guided experience; sometimes one or two doses total. |
| Typical cost | ~$150–$400/month (telehealth) to $400–$800/session (IV). | ~$1,000–$3,500 for a single legal Oregon session. |
| Where to get it | Clinics, certified Spravato offices, and telehealth nationwide. | Licensed service centers in Oregon and Colorado only. |
The two drugs act on different brain systems. Ketamine blocks the NMDA glutamate receptor. This triggers a burst of new synaptic connections that many researchers link to its fast antidepressant effect. You can read more in our full ketamine guide.
Technically, ketamine is a "dissociative anesthetic," not a classic psychedelic. It has been used in surgery and emergency rooms since 1970. At low therapeutic doses, it creates a floating, detached feeling. Most people stay aware of their surroundings the whole time.
Psilocybin works on the serotonin 5-HT2A receptor, like LSD and DMT. The brain becomes more flexible, and many people report deep emotional or mystical experiences. Our psilocybin guide covers the science in depth. This difference is why ketamine feels "dissociative" while psilocybin feels "psychedelic."
The experience itself also differs. A ketamine session lasts under an hour, and most people need a series of six or more to see lasting benefit. A psilocybin session lasts six to eight hours, with a trained guide present. Many psilocybin protocols use just one or two doses in total.
Psilocybin usually feels more intense and emotional. It can bring up memories, visions, and strong feelings over many hours. Ketamine feels more detached and dreamlike, and it ends faster. Neither is "better" here. The right choice depends on what you want from the experience.
Ketamine has the longer evidence track record in real-world care. A single sub-anesthetic dose can lift depression within hours.3 In January 2025, the FDA approved Spravato as the first standalone treatment for treatment-resistant depression, meaning patients no longer need to pair it with an oral antidepressant.2 The main weakness is durability. Benefits often fade without repeat dosing.
Psilocybin's data is newer but strong. In 2025, COMPASS Pathways reported that both of its Phase 3 trials of COMP360 psilocybin hit their primary endpoints for treatment-resistant depression.4 Earlier work by Carhart-Harris and colleagues also showed rapid, lasting improvement in some patients.5 Still, FDA review is ongoing, and you cannot get a psilocybin prescription today.
This is where ketamine and psilocybin split most clearly. Ketamine is a Schedule III drug. Doctors can prescribe it anywhere in the US, and telehealth options exist. Psilocybin is still Schedule I at the federal level. The only legal, regulated access is through licensed centers in Oregon (Measure 109) and Colorado (Proposition 122).6
That means you cannot fill a psilocybin prescription at a pharmacy. You also cannot legally mail-order it. To see how your state treats each drug, check our guide on what psychedelics are legal in the US.
Cost is a real barrier for psilocybin because each session is long and needs a trained facilitator present the whole time. Ketamine sessions are shorter and cheaper. Not sure which path fits your depression treatment goals? Try our depression treatment path tool to compare your real options.
Getting ketamine is the simpler path. You can find a clinic for IV infusions, a certified office for Spravato, or a telehealth provider for at-home lozenges. Quality varies, so ask about screening and follow-up. With telehealth especially, look for a real psychiatric evaluation, not a quick online form.
Getting psilocybin legally takes more planning. You must visit a licensed service center in Oregon or Colorado. You book an intake, a dosing session, and a follow-up. No prescription or doctor referral is needed, but you pay out of pocket. Many people travel from other states to take part.
Microdosing means taking very small amounts on a regular schedule. People microdose both ketamine and psilocybin, but the evidence is thin. Most controlled studies have not shown clear benefits over placebo. Microdosing psilocybin also stays illegal outside the regulated programs. Treat any microdosing claims with healthy caution.
Both drugs are generally safe under supervision but carry different risks. Ketamine can raise blood pressure, cause dissociation, and, with heavy long-term use, harm the bladder. Psilocybin can cause anxiety, nausea, and hard emotional experiences during the session.
Screening matters for both. A good provider checks your medical history, current medications, and mental health before you start. People with heart problems, uncontrolled blood pressure, or a history of psychosis may not be good candidates. Honest screening lowers your risk a lot.
Some people try ketamine first because it is easy to access, then explore psilocybin later if it becomes legal where they live. They are not usually combined in the same session. If you are weighing either drug for a specific condition, talk with a clinician who knows your full history. Good preparation and follow-up care improve results for both.
Depression is the strongest use case for both drugs. Ketamine also has growing data for suicidal thoughts and is used off-label for anxiety and chronic pain. Psilocybin is being studied for depression, anxiety in serious illness, and addiction.
Choose ketamine if you want a legal, available treatment now, need fast relief, have treatment-resistant depression, or want a chance at insurance coverage through Spravato. It is the only option you can access in every state today.
Choose psilocybin if you live in or can travel to Oregon or Colorado, want a single deep guided experience instead of repeat dosing, can pay out of pocket, and are comfortable waiting for full FDA approval. For most people, ketamine wins on access while psilocybin appeals on experience.
Still unsure which substance matches your goals? Take our which psychedelic quiz for a personalized starting point.
Both show real benefit for depression, but they fit different situations. Ketamine works within hours, is legal nationwide, and Spravato (esketamine) is FDA-approved, including as a standalone treatment since January 2025. Psilocybin had two positive Phase 3 trials in 2025 and may last longer from fewer doses, but it is not FDA-approved and is hard to access. For most people today, ketamine wins on availability while psilocybin appeals on the depth of a single experience.
Ketamine is the cheaper option. At-home telehealth lozenges run about $150 to $400 per month, and in-clinic IV infusions cost roughly $400 to $800 each, with Spravato often partly covered by insurance. A single legal psilocybin session in Oregon usually costs $1,000 to $3,500, and insurance does not cover it. Psilocybin costs more because each session is long and needs a trained facilitator the whole time.
No. Ketamine is a Schedule III drug, so doctors can prescribe it nationwide through clinics and telehealth. Psilocybin is still Schedule I federally, so you cannot fill a prescription or order it by mail. The only legal, regulated access is through licensed service centers in Oregon and Colorado, where you book and pay for sessions in person.
Ketamine is the more accessible choice for anxiety right now. Some clinics use it off-label, and early studies suggest it can reduce anxiety symptoms, though it is not FDA-approved for that use. Psilocybin shows promise for anxiety in research, especially anxiety tied to serious illness, but it remains experimental and is not approved. Always work with a licensed clinician, since neither is a guaranteed fix.
Not exactly. Ketamine is a dissociative anesthetic that blocks the NMDA glutamate receptor, while psilocybin is a classic psychedelic that activates the 5-HT2A serotonin receptor. Ketamine feels detached and dreamlike and lasts under an hour, whereas psilocybin feels more emotional and visual and lasts six to eight hours. They are often discussed together because both are studied for depression.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.